{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:37:55Z","timestamp":1789641475962,"version":"4.0.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.jhep.2015.01.026","type":"journal-article","created":{"date-parts":[[2015,1,31]],"date-time":"2015-01-31T09:43:06Z","timestamp":1422697386000},"page":"20-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"title":["Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir\/ritonavir, ombitasvir, and dasabuvir"],"prefix":"10.1016","volume":"63","author":[{"given":"Rajeev M.","family":"Menon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajakta S.","family":"Badri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshanth R.","family":"Polepally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuhong","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P.","family":"Coakley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Podsadecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid M.","family":"Awni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.01.026_b0005","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2015.01.026_b0010","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/hep.23528","article-title":"Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study","volume":"51","author":"Bruno","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2015.01.026_b0015","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.cgh.2011.05.028","article-title":"Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C","volume":"9","author":"Ng","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.01.026_b0020","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","article-title":"A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C","volume":"9","author":"Backus","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.01.026_b0025","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2012.10.027","article-title":"Clinical management of drug-drug interactions in HCV therapy: challenges and solutions","volume":"58","author":"Burger","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.026_b0030","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1016\/j.dld.2013.07.011","article-title":"Optimizing DAA management in daily practice","volume":"45","author":"Serfaty","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2015.01.026_b0035","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1016\/j.dld.2013.07.008","article-title":"The importance of drug-drug interactions in the DAA era","volume":"45","author":"Back","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2015.01.026_b0040","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.01.026_b0045","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.01.026_b0050","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.01.026_b0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","article-title":"ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection","volume":"147","author":"Andreone","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.01.026_b0060","unstructured":"Bow DAJ, Liu J, Kavetskaia O, Menon R, de Morais SM, Nijsen M, et al. A mechanistic non-clinical assessment of drug-drug interactions (metabolism and transporters) with the hepatitis C virus (HCV) regimen: ABT-450\/r, ombitasvir and dasabuvir. In: Poster presented at: 2014 American Association for the Study of Liver Diseases\/European Association for the Study of the Liver Special Conference on Hepatitis C; September 12\u201313, 2014; New York, NY."},{"key":"10.1016\/j.jhep.2015.01.026_b0065","unstructured":"United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Drug Interaction Studies \u2013 Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Draft Guidance; February 2012. Available from: <http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM292362.pdf>."},{"key":"10.1016\/j.jhep.2015.01.026_b0070","unstructured":"European Medicines Agency. Guideline on the Investigation of Drug Interactions. CPMP\/EWP\/560\/95\/Rev. 1, 21 June 2012. Available from: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf>."},{"key":"10.1016\/j.jhep.2015.01.026_b0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"Poordad","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.01.026_b0080","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1306227","article-title":"Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.01.026_b0085","first-page":"S42","article-title":"Population pharmacokinetics of ABT-450, ombitasvir, dasabuvir, ritonavir and ribavirin in subjects with HCV genotype 1 infection [abstract T-007]","volume":"41","author":"Mensing","year":"2014","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.jhep.2015.01.026_b0090","doi-asserted-by":"crossref","first-page":"S480","DOI":"10.1016\/S0168-8278(12)61222-7","article-title":"ABT-267 combined with pegylated interferon alpha-2a\/ribavirin in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12 week antiviral and safety analysis [abstract 1210]","volume":"56","author":"Sullivan","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.01.026_b0095","unstructured":"Gaultier IA, Cohen DE, Dumas EO, Larsen LM, Podsadecki TJ, Bernstein B. 12-Week efficacy and safety of ABT-072 or ABT-333 with pegylated interferon+ribavirin, following 3-day monotherapy in genotype 1 HCV-infected treatment-na\u00efve subjects. In: Poster presented at: 21st Conference of the Asian Pacific Association for the Study of the Liver; February 17-20, 2011; Bangkok, Thailand. <http:\/\/www.natap.org\/2011\/APSL\/APSL_02.htm>. Accessed October 17, 2014."},{"key":"10.1016\/j.jhep.2015.01.026_b0100","unstructured":"Rodriguez-Torres M, Lawitz E, Cohen D, Larsen LM, Menon R, Collins C, et al. Treatment-na\u00efve, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone [abstract LB6]. In: Presented at: The 60th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2009; October 30-November 3; Boston, MA."},{"key":"10.1016\/j.jhep.2015.01.026_b0105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/11539240-000000000-00000","article-title":"Duloxetine: clinical pharmacokinetics and drug interactions","volume":"50","author":"Knadler","year":"2011","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815000574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815000574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T22:21:04Z","timestamp":1537914064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815000574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0168827815000574"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.01.026","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir\/ritonavir, ombitasvir, and dasabuvir","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}